Viva In Vitro Diagnostics has been included as a reference Spanish biotechnology company in the report In Vitro Diagnostic (IVD) Devices in China, published by ICEX Spain Trade & Investment and prepared by the Economic and Commercial Office of Spain in Shanghai.
The publication provides an in-depth analysis of the evolution of the Chinese in vitro diagnostics market, its regulatory environment, growth opportunities, and the role of applied innovation in areas such as immunoassays, molecular diagnostics, advanced biomarkers and point-of-care solutions. Within this context, Viva In Vitro is highlighted as an example of the technological development emerging from the Spanish immunodiagnostics ecosystem.
Our inclusion in this report aligns with the work we are carrying out in immunological diagnostics based on NLRP3 inflammasome activation through ASC-specks detection, a scientific approach designed to improve early stratification of patients at risk of immunosuppression in critical care settings.
The ICEX analysis emphasises the growing demand in China for technologies focused on early detection, automation, new biomarker development, and personalised medicine, an environment consistent with the scientific and clinical advances pursued by Viva In Vitro.
This reference contributes to strengthening the international visibility of advanced diagnostic solutions developed in Spain, particularly those aimed at improving clinical management of complex inflammatory conditions and sepsis.